• Gene fusion; HGNC; HGNC:7135; AFF1 + HGNC; HGNC:7132; KMT2A; Name(s)=KMT2A-AFF1, MLL-AFF1, ALL-1/AF4 (from parent cell line).
  
• Mutation; HGNC; HGNC:3765; FLT3; Unexplicit; Internal tandem duplication (FLT3-ITD); ClinVar=VCV000016270; Zygosity=Unspecified (from parent cell line).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Heterozygous (PubMed=29491412; PubMed=29454094).
  

PubMed=29454094; DOI=10.1016/j.canlet.2018.02.018
Ulrike Tontsch-Grunt, Dorothea Rudolph, Irene C. Waizenegger, Anke Baum, Daniel Gerlach, Harald Engelhardt, Melanie Wurm, Fabio Savarese, Norbert Schweifer, Norbert Kraut;
Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML in vitro and in vivo.
Cancer Lett. 421:112-120(2018)

PubMed=29491412; DOI=10.1038/s41388-018-0150-2; PMCID=PMC5955861
Daniel Gerlach, Ulrike Tontsch-Grunt, Anke Baum, Johannes Popow, Dirk Scharn, Marco H. Hofmann, Harald Engelhardt, Onur Kaya, Janina Beck, Norbert Schweifer, Thomas Gerstberger ...Show all 14 authors... , Johannes Zuber, Fabio Savarese, Norbert Kraut; Show fewer authors
The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML.
Oncogene 37:2687-2701(2018)